Clicky

Ambrx Biopharma Inc.(AMAM)

Description: Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology.


Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Health Sciences Immunology Cancer Immunotherapy Antibody Drug Conjugate Oncology Therapies Beigene

Home Page: ambrx.com

AMAM Technical Analysis

10975 North Torrey Pines Road
La Jolla, CA 92037
United States
Phone: 858 875 2400


Officers

Name Title
Ms. Sonja Nelson CPA Chief Financial & Operating Officer
Mr. Daniel J. O'Connor J.D. CEO, Pres & Director
Dr. Ying J. Buechler Ph.D. Chief Technology Officer
Dr. Shawn Shao-Hui Zhang Ph.D. Chief Scientific Officer

Exchange: NYSE

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0.2363
Price-to-Book MRQ: 0.1116
Price-to-Sales TTM: 16.5982
IPO Date: 2021-06-18
Fiscal Year End: December
Full Time Employees: 81
Back to stocks